These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 38683066)
1. [Anything that can go wrong: cytotoxic cells and their control of Epstein-Barr virus]. Gutiérrez-Guerrero A; Espinosa-Padilla SE; Lugo-Reyes SO Rev Alerg Mex; 2024 Feb; 71(1):29-39. PubMed ID: 38683066 [TBL] [Abstract][Full Text] [Related]
2. Asymptomatic Primary Infection with Epstein-Barr Virus: Observations on Young Adult Cases. Abbott RJ; Pachnio A; Pedroza-Pacheco I; Leese AM; Begum J; Long HM; Croom-Carter D; Stacey A; Moss PAH; Hislop AD; Borrow P; Rickinson AB; Bell AI J Virol; 2017 Nov; 91(21):. PubMed ID: 28835490 [TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism. Serafini B; Rosicarelli B; Veroni C; Mazzola GA; Aloisi F J Virol; 2019 Dec; 93(24):. PubMed ID: 31578295 [TBL] [Abstract][Full Text] [Related]
4. The Epstein-Barr Virus Oncogene EBNA1 Suppresses Natural Killer Cell Responses and Apoptosis Early after Infection of Peripheral B Cells. Westhoff Smith D; Chakravorty A; Hayes M; Hammerschmidt W; Sugden B mBio; 2021 Dec; 12(6):e0224321. PubMed ID: 34781735 [TBL] [Abstract][Full Text] [Related]
9. Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity. Edwards ESJ; Bier J; Cole TS; Wong M; Hsu P; Berglund LJ; Boztug K; Lau A; Gostick E; Price DA; O'Sullivan M; Meyts I; Choo S; Gray P; Holland SM; Deenick EK; Uzel G; Tangye SG J Allergy Clin Immunol; 2019 Jan; 143(1):276-291.e6. PubMed ID: 29800648 [TBL] [Abstract][Full Text] [Related]
10. The evolution of antigen-specific CD8+ T cell responses after natural primary infection of humans with Epstein-Barr virus. Callan MF Viral Immunol; 2003; 16(1):3-16. PubMed ID: 12725684 [TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity in Epstein Barr virus specific immune control. Münz C Curr Opin Virol; 2021 Feb; 46():1-8. PubMed ID: 32771660 [TBL] [Abstract][Full Text] [Related]
12. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases. Cui X; Snapper CM Front Immunol; 2021; 12():734471. PubMed ID: 34691042 [TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells. Albanese M; Tagawa T; Bouvet M; Maliqi L; Lutter D; Hoser J; Hastreiter M; Hayes M; Sugden B; Martin L; Moosmann A; Hammerschmidt W Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6467-E6475. PubMed ID: 27698133 [TBL] [Abstract][Full Text] [Related]
14. Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases. Latour S; Fischer A Immunol Rev; 2019 Sep; 291(1):174-189. PubMed ID: 31402499 [TBL] [Abstract][Full Text] [Related]
15. Long-term carriers generate Epstein-Barr virus (EBV)-specific CD4(+) and CD8(+) polyfunctional T-cell responses which show immunodominance hierarchies of EBV proteins. Ning RJ; Xu XQ; Chan KH; Chiang AK Immunology; 2011 Oct; 134(2):161-71. PubMed ID: 21896011 [TBL] [Abstract][Full Text] [Related]
16. Severity of Acute Infectious Mononucleosis Correlates with Cross-Reactive Influenza CD8 T-Cell Receptor Repertoires. Aslan N; Watkin LB; Gil A; Mishra R; Clark FG; Welsh RM; Ghersi D; Luzuriaga K; Selin LK mBio; 2017 Dec; 8(6):. PubMed ID: 29208744 [TBL] [Abstract][Full Text] [Related]
17. Application of flow cytometric in situ hybridization assay to Epstein-Barr virus-associated T/natural killer cell lymphoproliferative diseases. Kawabe S; Ito Y; Gotoh K; Kojima S; Matsumoto K; Kinoshita T; Iwata S; Nishiyama Y; Kimura H Cancer Sci; 2012 Aug; 103(8):1481-8. PubMed ID: 22497716 [TBL] [Abstract][Full Text] [Related]
18. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy. Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498 [TBL] [Abstract][Full Text] [Related]
19. T/NK cell type chronic active Epstein-Barr virus disease in adults: an underlying condition for Epstein-Barr virus-associated T/NK-cell lymphoma. Isobe Y; Aritaka N; Setoguchi Y; Ito Y; Kimura H; Hamano Y; Sugimoto K; Komatsu N J Clin Pathol; 2012 Mar; 65(3):278-82. PubMed ID: 22247563 [TBL] [Abstract][Full Text] [Related]
20. Natural Killer cell transcriptome during primary EBV infection and EBV associated Hodgkin Lymphoma in children-A preliminary observation. M A; Chatterjee S; A P; S M; Davuluri S; Ar AK; T A; M P; Cs P; Sinha M; Chugani A; R VP; Kk A; R S J Immunobiology; 2020 May; 225(3):151907. PubMed ID: 32044149 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]